Last reviewed · How we verify
Anoro® Ellipta®
Anoro Ellipta combines a long-acting beta-2 agonist and a long-acting muscarinic antagonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.
Anoro® Ellipta® is a fixed-dose combination inhaler containing indacaterol maleate and glycopyrronium bromide, indicated for COPD. It has completed several clinical trials, demonstrating efficacy and safety. Despite no FDA label, it remains a key treatment option in COPD management.
At a glance
| Generic name | Anoro® Ellipta® |
|---|---|
| Also known as | Anoro® - Umeclidinium/Vilanterol, Ellipta® - Device, umeclidinium + vilanterol |
| Sponsor | AstraZeneca |
| Drug class | Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) |
| Target | Beta-2 adrenergic receptor and M3 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The drug contains umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-2 agonist). These two bronchodilators work synergistically through different pathways: the beta-2 agonist increases cAMP to relax smooth muscle, while the muscarinic antagonist blocks acetylcholine-mediated bronchoconstriction. Together they provide sustained bronchodilation and improved lung function in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anoro® Ellipta® CI brief — competitive landscape report
- Anoro® Ellipta® updates RSS · CI watch RSS
- AstraZeneca portfolio CI